Names

Presentations

Bonnefoi H.

Gene Signature and Response to Chemotherapy in Breast Cancer

Carbone D.

Proteomics

Chabannon C.

Cancer biobanking: The European perspective

Compton C.

Cancer biobanking: The American perspective

Diamandis E.

Novel biomarkers for prognosis and therapy response in ovarian cancer

Esteller M.

Epigenetics

Griffiths J.

MR Spectroscopy for patient stratification or tumor monitoring

Hayes D.

Assessment of biomarkers (report ASCO Guidelines) – HER2

Hegi M.

Biomarkers of Brain Tumors to Temozolamide Treatment

Jayson G.

DCE-MRI as biomarker of tumor angiogenesis

Johnson B.

Biomarkers of Lung Cancer Response to EGFR-TKI

Khan J.

microRNAs

Khleif S.

Perspectives from the U.S. FDA

Langenberg M.

Clinical decision making based on circulating endothelial (progenitor) cells: a help or a struggle?

Leyland-Jones B.

Report on BIG / North American Cooperative Groups harmonization of specimen collection and handling procedures

Mankoff D.

PET biomarkers: beyond FDG

Martin S.

Blood biobanking: Chances & risks

Mellinghoff I.

Biomarkers of Brain Tumors to EGFR-TKI

Michiels S.

Interpretation of microarray data in cancer: a statistical viewpoint

Passioukov A.

Riegman P.

Round table: Tissue and blood banking; harmonizing the activities

Penny S.

Systematic validation of novel breast cancer progression-associated biomarkers via high-throughputs antibody generation and application of tissue microarray technology: an initial report

Ross B.

Diffusion-weighted MRI as a predictive biomarker and to monitor treatment response

Schwartz L.

Are sized-based response criteria appropriate in the area of targeted therapy?

Soria J-C.

ERCC1 and Response to Chemotherapy

Sotiriou C.

Key messages learned from gene expression profiling studies in breast cancer

Spatz A.

Gene Signature and Outcome of Patients with Melanoma

Sullivan D.

Round table: How to evaluate and qualify imaging biomarkers in drug development and as a surrogate marker of clinical benefit?

Tejpar S.

Levels of amphiregulin and epiregulin expression correlate with overall survival in colorectal cancer treated with cetuximab

Thomas G.

Development of clinical biomarkers – the importance of SOPs and quality assurance

Warrington J.

Reproducibility

Weber W.

Value of FDG-PET as a surrogate marker of treatment response